Development of tumor vaccine on gynecologic cancer.
- Author:
Bo-lan XU
1
;
Yi LI
;
Heng CUI
Author Information
1. Gynecologic Oncology Center, People's Hospital, Peking University, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
biosynthesis;
immunology;
Dendritic Cells;
immunology;
Female;
Genetic Engineering;
Humans;
Ovarian Neoplasms;
immunology;
Papillomaviridae;
immunology;
Papillomavirus Infections;
immunology;
Uterine Cervical Neoplasms;
immunology;
Vaccines, DNA;
immunology
- From:
Acta Academiae Medicinae Sinicae
2003;25(4):487-491
- CountryChina
- Language:Chinese
-
Abstract:
The study of tumor vaccine is one of the focus of immunological therapy on malignant gynecologic cancer. All of the ovarian carcinoma vaccine are therapeutic, including cloned antigen vaccine, tumor cell vaccine, genetic engineering tumor cell vaccine, dendritic cell (DC) vaccine, as well as anti-idiotypic vaccine. The therapeutic vaccines based on human papillomavirus (HPV) of cervical cancer are mostly summarized, including polypeptides vaccine, carrier vaccine, fusion protein or chimeric vaccine, and DC vaccine. The preventive vaccine based on HPV of cervical cancer are briefly introduced. As there are only a few reports on endometrial carcinoma vaccine.
